scPharmaceuticals Inc. – NASDAQ:SCPH
scPharmaceuticals stock price today
$4.46
+1.04
+30.41%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
scPharmaceuticals stock price monthly change
-24.50%
month
scPharmaceuticals stock price quarterly change
-24.50%
quarter
scPharmaceuticals stock price yearly change
-46.56%
year
scPharmaceuticals key metrics
Market Cap | 170.63M |
Enterprise value | 228.90M |
P/E | -6.91 |
EV/Sales | N/A |
EV/EBITDA | -4.64 |
Price/Sales | N/A |
Price/Book | 3.62 |
PEG ratio | 0.25 |
EPS | -1.49 |
Revenue | 17.63M |
EBITDA | -57.90M |
Income | -57.70M |
Revenue Q/Q | 195.78% |
Revenue Y/Y | 754.67% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -328.41% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freescPharmaceuticals stock price history
scPharmaceuticals stock forecast
scPharmaceuticals financial statements
Average Price Target
$13
Potential upside: 191.47%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 1.63M | -14.15M | -864.1% |
|---|---|---|---|
| Sep 2023 | 3.79M | -15.63M | -411.85% |
| Dec 2023 | 6.09M | -13.81M | -226.57% |
| Mar 2024 | 6.10M | -14.10M | -231.2% |
| Jun 2023 | 114171000 | 50.74M | 44.45% |
|---|---|---|---|
| Sep 2023 | 106101000 | 56.95M | 53.68% |
| Dec 2023 | 94479000 | 57.26M | 60.61% |
| Mar 2024 | 78454000 | 53.88M | 68.69% |
| Jun 2023 | -14.14M | 9.42M | 611K |
|---|---|---|---|
| Sep 2023 | -13.45M | -22.92M | 68K |
| Dec 2023 | -15.15M | 26.46M | 467K |
| Mar 2024 | -17.70M | 29.31M | 15K |
scPharmaceuticals alternative data
| Aug 2023 | 96 |
|---|---|
| Sep 2023 | 96 |
| Oct 2023 | 96 |
| Nov 2023 | 96 |
| Dec 2023 | 96 |
| Jan 2024 | 96 |
| Feb 2024 | 96 |
| Mar 2024 | 135 |
| Apr 2024 | 135 |
| May 2024 | 135 |
| Jun 2024 | 135 |
| Jul 2024 | 135 |
scPharmaceuticals other data
58.07%
-0.19%
of SCPH is owned by hedge funds
15.88M
-53.13K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2021 | 15000 | 0 |
| Apr 2022 | 0 | 270000 |
| Sep 2022 | 0 | 226622 |
| Oct 2022 | 0 | 562466 |
| Nov 2022 | 762380 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | ORBIMED ADVISORS LLC 10 percent owner | Common Stock | 762,380 | $5.25 | $4,002,495 | ||
Sale | 5AM PARTNERS IV, LLC 10 percent owner | Common Stock | 19,017 | $4.09 | $77,780 | ||
Sale | 5AM PARTNERS IV, LLC 10 percent owner | Common Stock | 456,413 | $4.09 | $1,866,729 | ||
Sale | 5AM PARTNERS IV, LLC 10 percent owner | Common Stock | 87,036 | $4.09 | $355,977 | ||
Option | TUCKER JOHN H director, officer.. | Restricted Stock Units | 42,250 | N/A | N/A | ||
Option | TUCKER JOHN H director, officer.. | Common Stock | 42,250 | N/A | N/A | ||
Sale | 5AM PARTNERS IV, LLC 10 percent owner | Common Stock | 30,173 | $4.75 | $143,322 | ||
Sale | 5AM PARTNERS IV, LLC 10 percent owner | Common Stock | 6,793 | $4.75 | $32,267 | ||
Sale | 5AM PARTNERS IV, LLC 10 percent owner | Common Stock | 163,034 | $4.75 | $774,412 | ||
Sale | 5AM PARTNERS IV, LLC 10 percent owner | Common Stock | 4,016 | $5.52 | $22,168 |
| Patent |
|---|
Application Filling date: 18 Feb 2022 Issue date: 2 Jun 2022 |
Application Filling date: 30 Jan 2020 Issue date: 31 Mar 2022 |
Application Filling date: 7 Mar 2019 Issue date: 6 Feb 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2024 14 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 13 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 8 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 10 Aug 2023 | Q2 2023 Earnings Call Transcript |
scPharmaceuticals Q3 Earnings: Cruising Toward Success
scPharmaceuticals: Furoscix, Charting A Bright Future With FDA's Nod For CKD
Sizing Up scPharmaceuticals
scPharmaceuticals: Oversold Territory, Drug Launch Still Looks Robust
scPharmaceuticals: Furoscix Firing On All Cylinders In Q1, Bullish Than Ever
Avadel Pharmaceuticals: Lumryz Approved, Launch Expected June 2023 And We Remain Bullish
scPharmaceuticals: Undervalued, De-Risked Cardiology Commercial Biotech, Initiating With A Buy
scPharmaceuticals: Furoscix Approval A Potential Paradigm Shift For Heart Failure Patients
scPharmaceuticals: We Still See A High Probability Of Success For FUROSCIX
-
What's the price of scPharmaceuticals stock today?
One share of scPharmaceuticals stock can currently be purchased for approximately $4.46.
-
When is scPharmaceuticals's next earnings date?
Unfortunately, scPharmaceuticals's (SCPH) next earnings date is currently unknown.
-
Does scPharmaceuticals pay dividends?
No, scPharmaceuticals does not pay dividends.
-
How much money does scPharmaceuticals make?
scPharmaceuticals has a market capitalization of 170.63M.
-
What is scPharmaceuticals's stock symbol?
scPharmaceuticals Inc. is traded on the NASDAQ under the ticker symbol "SCPH".
-
What is scPharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of scPharmaceuticals?
Shares of scPharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are scPharmaceuticals's key executives?
scPharmaceuticals's management team includes the following people:
- Mr. John H. Tucker Pres, Chief Executive Officer, Principal Executive Officer, Principal Financial Officer & Director(age: 62, pay: $780,460)
- Ms. Rachael Nokes Senior Vice President of Fin. & Principal Accounting Officer(age: 50, pay: $433,540)
-
How many employees does scPharmaceuticals have?
As Jul 2024, scPharmaceuticals employs 135 workers.
-
When scPharmaceuticals went public?
scPharmaceuticals Inc. is publicly traded company for more then 7 years since IPO on 17 Nov 2017.
-
What is scPharmaceuticals's official website?
The official website for scPharmaceuticals is scpharmaceuticals.com.
-
Where are scPharmaceuticals's headquarters?
scPharmaceuticals is headquartered at 2400 District Avenue, Burlington, MA.
-
How can i contact scPharmaceuticals?
scPharmaceuticals's mailing address is 2400 District Avenue, Burlington, MA and company can be reached via phone at +61 75170730.
-
What is scPharmaceuticals stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for scPharmaceuticals in the last 12 months, the avarage price target is $13. The average price target represents a 191.47% change from the last price of $4.46.
scPharmaceuticals company profile:
scPharmaceuticals Inc.
scpharmaceuticals.comExchange:
NASDAQ
Full time employees:
135
Industry:
Biotechnology
Sector:
Healthcare
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
2400 District Avenue
Burlington, MA 01803
Burlington, MA 01803
CIK: 0001604950
ISIN: US8106481059
CUSIP: 810648105
